Transgene, Sillajen, Lee’s partner to bring liver cancer immunotherapy forward
HONG KONG – A Hong Kong-based biotechnology company that specializes in in-licensing products for marketing in China will work with a partner in South Korea and one in Europe in a late-stage clinical development program for the oncolytic immunotherapy Pexa-Vec (JX-594/TG6006).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST